Sileny Han

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

B.J. Rimel, Eric Pujade‐Lauraine, Kathleen Moore, Jacobus Pfisterer et autres

us, fr, de, be, cz, nl, es, gr, il, it, gb, dk, pl, ca, fi, Nigéria, jp (code pays fourni par la source)

Quality-adjusted time without symptom or toxicity and quality-adjusted progression-free survival of first-line maintenance niraparib in patients with advanced ovarian cancer

Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri et autres

es, kr, us, be, dk, fi, jp, it, fr, de, gb (code pays fourni par la source)

Additional file 9 of High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Siel Olbrecht, Pieter Busschaert, Jun Qian, Adriaan Vanderstichele et autres

571 Niraparib in patients with newly diagnosed advanced ovarian brcam cancer: a post hoc analysis of the prima/engot-ov26/gog-3012 trial

Jacob Korach, Whitney A. Spannuth Graybill, Andrés Redondo, David M. O’Malley et autres

us, il, at, es, be, dk, fi, nl (code pays fourni par la source)

Pragmatic, Non-Interventional Study of Clofarabine in Korean Pediatric Patients with Acute Lymphoblastic Leukemia Who Failed to Respond or Relapsed After 2 More Regimen

Jun Yong Choi, H. Y. Shin, Kevin Hong, Hua Kang et autres

Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.

Adriaan Vanderstichele, Els Van Nieuwenhuysen, Sileny Han, Nicole Concin et autres

be (code pays fourni par la source)